Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.69 |
| ▸ | CTSS | P25774 | 4/20 | 0.69 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9827468 | 0.94 | CTSK (0.62) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL9828093 | 0.94 | CTSK (0.62) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL9827486 | 0.94 | CTSK (0.62) | CTSKCTSSHDAC4HDAC1HDAC6 | |
| SCHEMBL345582 | 0.94 | CTSK (0.68) | CTSKCTSS | |
| SCHEMBL3448997 | 0.94 | CTSK (0.68) | CTSKCTSS | |
| SCHEMBL1350139 | 0.94 | CTSK (0.68) | CTSKCTSS | |
| Hydrochloric Acid SCHEMBL6037571 | 0.92 | CTSK (0.66) | CTSKCTSS | |
| SCHEMBL30423657 | 0.92 | CTSK (0.63) | CTSKCTSSRENHDAC4HDAC1 | |
| SCHEMBL3233192 | 0.89 | CTSK (0.62) | CTSKCTSS | |
| SCHEMBL18875931 | 0.89 | CTSK (0.62) | CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2025-07-31 | — | — | US | disclosed |
| US-12138292-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2024-11-12 | — | — | US | disclosed |
| CN-110022896-B | Novel compounds and therapeutic uses thereof | 森陶里治疗有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20220313776-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-10-06 | — | — | US | disclosed |
| US-11406683-B2 | Compounds and therapeutics uses thereof | Centauri Therapeutics Limited (GB/GB) (GB) | 2022-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11406683-B2 | Compounds and therapeutics uses thereof | MYD88, MAVS, CD47 | CTSK 214/4885CTSS 200/4885REN 1899/4885 |
| US-20220313776-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | CTSK 268/4885CTSS 234/4885REN 2363/4885 |
| US-12138292-B2 | Compounds and therapeutics uses thereof | MYD88, MAVS, CD47 | CTSK 214/4885CTSS 200/4885REN 1899/4885 |
| US-20250241979-A1 | NOVEL COMPOUNDS AND THERAPEUTICS USES THEREOF | MAVS, MYD88, CD47 | CTSK 268/4885CTSS 234/4885REN 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.